Record high egg prices affecting local diner's employees
WICHITA, Kan. (KSNW) — Egg prices are high across the country, record highs according to article by the Associated Press. Breakfast spots in Wichita are feeling the change. Many, like Riverside Cafe, are working to offset costs.
The diner is charging an additional 50 cent charge per egg. The cost is having a top-down effect, impacting workers as well as customers.
'They always ask us. Posted on the door is an additional 50 cents for an egg and they want to know what's going on,' David Davis, kitchen manager said.
Davis has worked at Riverside Cafe for over ten years and never seen prices this high.
'I remember when Bird Flu hit the first time, prices did go a little bit high. But right now a carton of eggs costs us $88 a carton and they're usually about $26,' Davis said.
Everybody at the cafe is feeling the impact.
'Everybody's struggling right now. With the price of everything,' dishwasher Jennie Bleese said.
'I know my money's not that good anymore, I've even had people say they're probably not going to come back because of the price of eggs,' server Megan Busby said. 'I just hope the prices of eggs go back down, I don't know and people to know that it's not our fault.'
Workers say the higher prices mean smaller tips. Busby says she knows everybody is hurting, but urges customers to understand their situation.
Despite the strain on paychecks, Davis says it won't impact their quality of service.
'I can't slash nobody's prices, so I just give them the best service I can give them' he said.
KSN also reached out to other diners in the area and almost all of them were struggling with similar financial troubles. Most are compensating with a slight price increase or utilizing egg alternatives.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox Sports
8 hours ago
- Fox Sports
Snake eyes: D-backs' $425 million investment in starting pitching hasn't gone as planned
Associated Press PHOENIX (AP) — The normally budget-conscious Arizona Diamondbacks have been willing to spend big money over the past several years, taking chances on the notoriously volatile market of free agent starting pitching. So far, it's a bet that has come up snake eyes. Over the past 5 1/2 years, Diamondbacks owner Ken Kendrick has committed roughly $425 million to four pitchers — Corbin Burnes, Jordan Montgomery, Eduardo Rodriguez and Madison Bumgarner. The combined return on that investment: A 30-48 record, 5.25 ERA, minus-0.4 WAR and two Tommy John surgeries. Yikes. The latest bad news came on June 1 when Burnes — who signed a $210 million, six-year deal in January — abruptly left a game against the Nationals with right elbow pain. Now he's set to undergo Tommy John surgery and might not return to the mound until 2027. It's a brutal blow for the D-backs, who have a 31-34 record heading into Monday night's game against the Mariners. The 30-year-old Burnes seemed like the safest bet on the market last winter when the D-backs made the signing. The four-time All-Star and 2021 National League Cy Young Award winner had been remarkably consistent and healthy over the previous four seasons, making at least 28 starts every year. 'I might as well do another job if we're going to be scared of bringing in a guy of this caliber on your team,' Arizona's general manager Mike Hazen said at Burnes' introductory news conference. Added Kendrick: 'We're stretching the budget. It won't be the last time.' And for two months, he was everything Hazen, Kendrick and the D-backs hoped for with a 3-2 record and 2.66 ERA. Now he's out for the foreseeable future. It's the latest in a bad run of luck for Arizona's front office. It's also a brutal reminder of the substantial risk in handing out big money to pitchers in an era when injuries are happening at an alarming rate. The D-backs aren't the only team facing the same problem, even in their own division. The Los Angeles Dodgers currently have 14 pitchers on the injured list — including starters Blake Snell, Tyler Glasnow, Roki Sasaki and Tony Gonsolin. Snell has made just two starts this season because of injuries after signing a $182 millon, five-year deal in the offseason. The difference is the Dodgers seem to have nearly unlimited money to keep adding talent. The D-backs do not. The string of disappointing signings started in December 2019, when the D-backs added Bumgarner with a $85 million, five-year deal. The lefty had declined from his peak in the early-to-mid 2010s, when he led the San Francisco Giants to three World Series titles, but there was reason to believe he would be a solid middle-of-the-rotation option. Instead, he regressed even more in the desert, going 15-32 with a 5.23 ERA over a little more than three seasons. The D-backs released him in 2023 after he had a 10.26 ERA through four starts, eating more than $30 million in the process. The D-backs made a surprise run to the World Series that year and invested in a pair of pitchers — Montgomery and Rodriguez — during the ensuing offseason. Montgomery signed a $25 million, one-year deal with a vesting option for 2025. Rodriguez was added on an $80 million, four-year deal. Much like the Bumgarner signing, both seemed like good deals at the time. Montgomery had just helped the Rangers beat the Diamondbacks in the World Series and was a solid lefty with a sub-4.00 ERA in each of the previous three seasons. Rodriguez was coming off one of the best seasons of his career after going 13-9 with a 3.30 ERA for the Detroit Tigers. Things haven't worked out for either pitcher. Montgomery was awful in 2024 with a 6.23 ERA and eventually demoted to the bullpen. But because he made 21 starts, his vesting option for $22.5 million kicked in for 2025. His bid for a bounce-back season ended before it even started. The lefty got hurt during spring training in March and needed Tommy John surgery for the second time in his career, ending his time in the desert. Rodriguez hurt his shoulder during spring training in 2024 and didn't make his D-backs debut until August, contributing a 5.04 ERA as the team faded down the stretch and missed the playoffs. He's battled injuries and ineffectiveness again this year with a 6.70 ERA through 10 starts. There's still time for the Rodriguez and Burnes deals to take a turn for the better. Even if Burnes doesn't return until 2027, he'd have four more years remaining on his deal. D-backs manager Torey Lovullo chose to remain optimistic following Burnes' injury. 'We're all with Corbin right now,' Lovullo said. 'This is a tough day to get this news. But we'll find a way to rally around him, play hard for him all year long. ... It's a long road, and it takes time for him to heal and recover. And he will. He'll be great for the Arizona Diamondbacks, I'm convinced of it.' ___ AP MLB: recommended
Yahoo
14 hours ago
- Yahoo
US, China hold trade talks in London amid high tensions over tariffs
(NewsNation) — President Donald Trump's top trade advisers are set to negotiate with Chinese officials in London on Monday in the latest attempt to reach a deal and ease the friction with China. Tensions over tariffs and supply chain disruptions were high heading into the meeting between Treasury Secretary Scott Bessent, Commerce Secretary Howard Lutnick, U.S. Trade Representative Jamieson Greer and their Chinese counterparts. The talks are expected to last at least a day, the Associated Press reported. In fight with Columbia, Trump seeks 'death sentence' Last week, Trump and Chinese leader Xi Jinping spoke via phone. Trump said on social media the call reached a 'very positive conclusion' and teased Monday's talks: 'Our respective teams will be meeting shortly at a location to be determined.' Both sides have accused each other of breaking a month-old deal to roll back triple-digit tariffs for 90 days, which was agreed upon during last month's meeting in Geneva. The White House is optimistic about reeling in the trade deficit with China, which was nearly $300 billion last year, according to the U.S. Trade Representative's Office. Speaker Johnson teases follow-ups to the 'one big, beautiful bill' 'President Trump, being a deal maker, talked with President Xi, and he said, let's take, you know, our senior guys and the people who are the same level as you. Let's have them meet somewhere, and let's get these things cleared up,' Kevin Hassett, director of the U.S. National Economic Council, told reporters Sunday. 'He literally said I want to meet in London and shake hands on it, so we know we've got a deal,' Hassett continued. Despite positive posturing, there is plenty for the two countries to disagree on during Monday's meeting. The Commerce Department has warned U.S. companies against using Chinese semiconductor chips, saying they could violate the nation's export rules. Another point of contention is the flow of rare earth minerals to the United States. China is a top producer of those minerals, which are used in the production of cars, cell phones, robots and military equipment. The U.S. has called for China to lift export restrictions on the minerals, and China could use that as leverage in Monday's talks. GOP braces for first 'test run' on codifying DOGE cuts Another likely topic of discussion is the Trump administration's recent decision to revoke visas for Chinese college students studying in 'critical fields' with alleged ties to China's Communist Party. According to a report from the Institute of International Education, nearly 250,000 college students from China were enrolled in the U.S. during the 2023-24 school Commerce Ministry has accused the U.S. of provoking frictions between the two sides. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
15 hours ago
- Yahoo
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growth HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologics advances toward its Phase 1/2 clinical trial for diabetic foot ulcers in the second half of 2025 and continues to expand its fibroblast-based therapeutic platform. 'Jason brings exactly the kind of experience and leadership we need at this pivotal moment. His deep understanding of public company operations and capital markets isn't just helpful — it's a force multiplier as we move our lead program into the clinic. He knows how to raise capital in a complex biotech environment, and that makes him a critical part of our mission to drive long-term innovation and deliver exceptional value to shareholders,' commented Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer. Mr. Davis added, 'FibroBiologics, with its fibroblast-based platform, strong intellectual property portfolio, and well-defined clinical strategy, offers a truly differentiated approach to the development of therapeutics and potential cures for chronic diseases, and has all the elements of a high-growth, high-impact enterprise. I'm excited to bring my experience in public company finance to the table as we execute, scale, and deliver meaningful value — not just for shareholders, but for patients around the world.' Mr. Davis most recently served as Chief Financial Officer of Virax Biolabs, where he helped navigate the company through its successful IPO in July 2022. During his tenure, he led multiple capital raises with favorable terms, managed all periodic reports and other filings with the SEC, and implemented public company governance best practices. Prior to Virax, Mr. Davis served in various finance roles for several public companies, including HyperDynamics Corp, where he increased the company's market cap from $20 million to over $700 million and raised over $200 million in multiple transactions from U.S. and European capital markets. He received his B.B.A. in Accounting from the University of Houston and is a CPA certified in Texas. For more information, please visit FibroBiologics' website or email FibroBiologics at info@ Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the timing of, clinical trials, and the role to be played by, and impact of, the Chief Financial Officer. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347)
